Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Major Program
Cancer Prevention Clinical Trials Network
Research Group
Prostate and Urologic Cancer
Sponsor
National Cancer Institute (NCI)
Status
Recruiting
NCT ID
NCT06022822
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg daily dose of Uro-A in two 250 mg capsules PO BID or two placebo capsules BID daily for 3 to 6 weeks prior to RP. The primary endpoint is to determine the effect of Uro-A on decreasing prostate tumor tissue oxidative stress (measured by 8-OHdG) compared to placebo.
Intervention
Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement
Condition
Prostate Adenocarcinoma
Investigators
Stephen J Freedland, Ashley E. Ross, David F. Jarrard, Judd W. Moul, Scott E. Eggener
CT Research Area
Prevention

See list of participating sites